Fig. 3

In vivo study of the anti-COPD pharmacological mechanism of ISOF. A: Validation of mRNA expression levels of Pik3c3, Aqp4, and Spp1; B: Western blot of PIK3C3, AQP4, and SPP1 protein expression in rat lung tissues, n = 4; C: Quantification of PIK3C3, AQP4, and SPP1 expression; D: Western blot of p-AKT, AKT, mTOR and p-mTOR (S2448 and S2481) protein expression; E: Quantification of p-AKT, AKT, MTOR and p-MTOR (S2448 and S2481) expression; F: Correlation analysis of p-AKT protein expression on PIK3C3, AQP4, SPP1, AKT, MTOR and p-MTOR protein expression, n = 12; G: Correlation analysis of AQP4 (DEGs) on PIK3C3 and SPP1 in expression profiling by array with clinical samples, n = 4. GAPDH was homogenized as an internal reference, *P < 0.05, and **P < 0.01 vs. the Model groups